Immunotherapy has proven to be effective against many serious diseases. But to treat diseases in the brain, the antibodies must first get past the obstacle of the blood-brain barrier. In a new study, a research group at Uppsala University describes their development of a new antibody design that increases brain uptake of antibodies almost 100-fold.
Immunotherapy entails treatment with antibodies; it is the fastest growing field in pharmaceutical development. In recent years, immunotherapy has successfully been used to treat cancer and rheumatoid arthritis, and the results of clinical studies look very promising for several other diseases. Antibodies are unique in that they can be modified to strongly bind to almost any disease-causing protein. In other words, major potential exists for new antibody-based medicines.
The problem with immunotherapy for diseases affecting the brain is that the brain is protected by a very tight layer of cells, called the blood-brain barrier. The blood-brain barrier effectively prevents large molecules, such as antibodies, from passing from the bloodstream into the brain. It has therefore been difficult to use immunotherapy to treat Alzheimer’s and Parkinson’s disease, which affect the brain, as well as cancerous tumours in the brain.
It has been known for a long time that some large proteins are actively transported across the blood-brain barrier. These include a protein called transferrin, whose primary task is to bind to iron in the blood and then transport it to the brain. The research group behind this new study has taken advantage of this process and modified the antibodies they want to transport into the brain using components that bind to the transferrin receptor. Then, like a Trojan horse, the receptor transports antibodies into the brain. The number of modifications to and placement of the antibodies have proven to be important factors for making this process as effective as possible.
“We’ve placed them so that each antibody only binds with one modification at a time, despite being modified in two places. Our design thus doubles the chances of the antibody binding to the transferrin receptor compared with only one modification. We’ve successfully increased the amount of antibodies in the brain almost 100-fold, which is the largest uptake improvement that has ever been shown,” says Greta Hultqvist, researcher at the Department of Public Health and Caring Sciences at Uppsala University.
To try out the new format, researchers have used it on an antibody that binds to a protein involved in the course of Alzheimer’s disease. Without the modification, they could only detect very small quantities of antibody in the brain in a mouse model of Alzheimer’s disease, while they could detect high levels of the modified antibody in the same mice.
“From a long-term perspective, it’s likely that the new format can be used to effectively treat not only Alzheimer’s disease, but also other diseases affecting the brain,” says Dag Sehlin, researcher at the Department of Public Health and Caring Sciences at Uppsala University.
Learn more: New antibody design opens door for brain treatments
[osd_subscribe categories=’immunotherapy’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “IMMUN0THERAPY”‘]
Receive an email update when we add a new IMMUN0THERAPY article.
The Latest on: Immunotherapy
[google_news title=”” keyword=”immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunotherapy
- Biotech CEL-SCI gets FDA go-ahead to conduct investigational cancer immunotherapy studyon May 8, 2024 at 11:18 am
Listen to this article CEL-SCI Corporation, the Vienna, Virginia-based biotechnology company with operations in Baltimore, Wednesday received approval from the U.S. Food and Drug Administration to ...
- Clinical trials show promise in oral immunotherapy to tackle food allergieson May 8, 2024 at 9:07 am
Two years into its three-year run, The Natasha Foundation has seen positive results from its clinical trial aiming to help desensitise children with food allergies using a technique known as oral ...
- Can Vitamin D Improve Cancer Immunotherapy?on May 8, 2024 at 6:30 am
Your diet could impact your cancer treatment’s progress; a new preclinical study suggests more vitamin D could improve responses to checkpoint inhibitors.
- Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meetingon May 8, 2024 at 4:45 am
Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said investigators will present new results from a phase 2 ...
- AI-driven model identifies potent cancer-killing immune cells for personalized immunotherapyon May 7, 2024 at 9:46 pm
Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer ...
- Study uncovers at least one cause of roadblocks to cancer immunotherapyon May 6, 2024 at 9:39 am
"These findings uncover new tactics that are employed by cancer to escape from immune cell attack and explain why some cancer immunotherapy strategies do not work well in the clinic," said Lieping ...
- Many Patients With Advanced MCC Not Receiving Immunotherapyon May 5, 2024 at 9:36 pm
Despite improved survival rates and guideline recommendations, many eligible patients with metastatic Merkel cell carcinoma are not receiving immunotherapy.
- Immunotherapy: A Beacon of Hope in Cancer Treatmenton May 4, 2024 at 2:25 pm
Cancer, a disease that has plagued humanity for centuries, has finally met its match in immunotherapy, a revolutionary treatment that harnesses the power of the immune system to combat this deadly ...
- Ketone supplement may boost immunotherapy against prostate canceron May 2, 2024 at 9:00 am
Researchers have found that adding a pre-ketone supplement to immunotherapy boosted its effectiveness against prostate cancer in mouse models.
via Bing News